Back to today’s briefing

Story perspectives

Korean Biopharma Firms Prepare for US Tariffs

2/16/2025

45 4

Summary

Story summary

Korean biopharmaceutical companies are bracing for potential US tariffs on their exports, as announced by President Trump. In response, firms like Celltrion and SK Biopharmaceuticals are exploring the establishment of production facilities in the US. This shift reflects the industry's urgent need for collaboration and strategic planning to navigate the turbulent trade landscape and safeguard their market presence.

1 of 1

Story summary

Korean biopharmaceutical companies are bracing for potential US tariffs on their exports, as announced by President Trump. In response, firms like Celltrion and SK Biopharmaceuticals are exploring the establishment of production facilities in the US. This shift reflects the industry's urgent need for collaboration and strategic planning to navigate the turbulent trade landscape and safeguard their market presence.